Welcome to our dedicated page for Applied Therapeutics SEC filings (Ticker: APLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial readouts, FDA meetings, and frequent capital raises make Applied Therapeutics’ SEC filings both crucial and complex. Skimming a 250-page 10-K to learn whether govorestat met its Phase 3 endpoints or how long cash reserves will last can cost hours.
Stock Titan solves that problem. Our AI-powered summaries break down each Applied Therapeutics annual report 10-K simplified section by section—R&D expense trends, orphan-drug milestones, and going-concern language—so you understand the story, not just the jargon. Real-time alerts push every Applied Therapeutics 8-K material events explained notice to your dashboard, while insider trading Form 4 transactions are streamed the moment executives buy or sell shares.
Need specific answers? Type a natural question—“How much dilution did APLT’s last S-3 cause?”—and get instant context drawn from the filing text. Our coverage spans:
- 10-Q updates for quarter-over-quarter burn analysis (Applied Therapeutics quarterly earnings report 10-Q filing)
- Form 4 insider transactions real-time to track executive stock moves (Applied Therapeutics executive stock transactions Form 4)
- DEF 14A proxy statement executive compensation details
- 8-K clinical data releases and financing announcements
Whether you’re modeling cash runway, monitoring Applied Therapeutics insider trading Form 4 transactions, or seeking a plain-English explanation of pipeline risks, our platform keeps you ahead with complete, continuously updated SEC coverage and concise AI insights.
Medicus Pharma Ltd. (NASDAQ: MDCX) filed Prospectus Supplement No. 3 to register 2.26 million common shares issuable from outstanding public warrants (exercise price $4.64; expiry Nov 15 2029). The supplement incorporates an accompanying Current Report detailing the issuance of a $2.5 million third debenture to YA II PN, Ltd. (Yorkville) on June 17 2025, the final tranche under a previously disclosed $5 million secured debenture facility.
Key terms of the Yorkville financing
- Total debenture principal issued to date: $5 million (three tranches of $1.25 m, $1.25 m and $2.5 m)
- Aggregate net proceeds received: $4.5 million after original-issue discounts
- Coupon: 8.0% annual; increases to 18.0% upon default
- Maturity: February 2 2026; guaranteed by all subsidiaries via a global guaranty
The transaction strengthens near-term liquidity but layers additional secured debt on the balance sheet and introduces accelerated interest-rate risk in the event of default. The warrants remain out-of-the-money (share price $2.58 vs. strike $4.64), limiting immediate dilution yet signaling potential future share issuance if the stock appreciates.
Investors should weigh the improved cash position against a compressed maturity schedule, 8% fixed interest expense, and a possible 18% penalty rate, as well as eventual equity dilution from both the debenture terms (if convertible) and registered warrants.
FAQ
What is the current stock price of Applied Therapeutics (APLT)?
What is the market cap of Applied Therapeutics (APLT)?
What is the primary focus of Applied Therapeutics?
Which diseases are targeted by their drug candidates?
How does Applied Therapeutics approach drug development?
What is the significance of ARI technology in their pipeline?
How does the company distinguish itself in a competitive market?
What therapeutic areas does Applied Therapeutics serve?
What does a clinical-stage biopharmaceutical company mean?
How does Applied Therapeutics engage with regulatory agencies?
